NYMXF Projected Dividend Yield

Nymox Pharmaceutical Corp ( OTCBB : NYMXF )

Nymox Pharmaceutical is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia and the treatment of low-grade localized prostate cancer. Co. has developed and markets NicAlert™ and TobacAlert™, which are test strips for determining whether a person is using tobacco products (NicAlert™) or has been exposed to second-hand smoke (TobacAlert™). Both NicAlert™ and TobacAlert™ employ the patented technology of Co.'s subsidiary, Serex, Inc., to provide a read-out of levels of cotinine, a by-product of the body's breakdown of nicotine and generally regarded as the indicator of tobacco exposure for smokers and nonsmokers.

20 YEAR PERFORMANCE RESULTS